Evidence map›Paper›PMID 25704671›Full record

ArticleJournal of cellular and molecular medicine2015

Sulindac has strong antifibrotic effects by suppressing STAT3-related miR-21.

Xue Zhou, You-Jie Li, Shu-Yan Gao, Xiao-Zhi Wang, Ping-Yu Wang, Yun-Fei Yan, Shu-Yang Xie, Chang-Jun Lv

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. More than a Genetic Code: Epigenetics of Lung Fibrosis.Molecular diagnosis & therapy · 2020
    Review
  5. Article
  6. Novel Anti-fibrotic Therapies.Frontiers in pharmacology · 2017
    Review
  7. Article
  8. Article
  9. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xue ZhouDepartment of Clinical Medicine, Binzhou Medical University, Yantai, China; Key Laboratory of Tumour Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
You-Jie Li
Shu-Yan Gao
Xiao-Zhi Wang
Ping-Yu Wang
Yun-Fei Yan
Shu-Yang Xie
Chang-Jun Lv
Binzhou Medical University · CNBinzhou University · CNShengli Oilfield Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a disease with an unknown cause and a poor prognosis. In this study, we aimed to explore the pathogenesis of PF and the mechanism of sulindac in attenuating bleomycin (BLM)-induced PF. The rat PF model was induced by BLM and verified through histological studies and hydroxyproline assay. The severity of BLM-induced PF in rats and other effects, such as the extent of the wet lung to bw ratios, thickening of alveolar interval or collagen deposition, was obviously ameliorated in sulindac-treated rat lungs compared with BLM-induced lungs. Sulindac also reversed the epithelial mesenchymal transition (EMT) and inhibited the PF process by restoring the levels of E-cadherin and α-smooth muscle actin (SMA) in A549 cells. Our results further demonstrated that the above effects of sulindac might be related to regulating of interferon gamma (IFN-γ) expression, which further affects signal transducers and activators of transcription 3 (STAT3) and phosphorylated STAT3 (p-STAT3) levels. Moreover, higher miR-21 levels with the decreased E-cadherin and increased α-SMA expressions were found in transforming growth factor-β1-treated A549 cells, which can be reversed by sulindac. Collectively, our results demonstrate that by decreasing IFN-γ-induced STAT3/p-STAT3 expression to down-regulate miR-21, sulindac could significantly reverse EMT in A549 cells and prevent BLM-induced PF.

Indexed as

ActinsAnimalsAnti-Inflammatory Agents, Non-SteroidalBleomycinBlotting, WesternCadherinsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleGene ExpressionHumansInterferon-gammaLungMicroRNAsMicroscopy, FluorescencePulmonary FibrosisActa2 protein, ratActinsAnti-Inflammatory Agents, Non-SteroidalBleomycinCadherinsInterferon-gammaMicroRNAsmirn21 microRNA, ratStat3 protein, ratSTAT3 Transcription FactorSulindacepithelial mesenchymal transitionIFN-γmiRNApulmonary fibrosisSTAT3sulindac

Identifiers

PMID25704671
PMCPMC4420612
OpenAlexW2086071724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.